Today's Issue

Main Topic: What the new obesity data shows, why GLP-1 drugs are almost certainly the primary driver, what the numbers look like by age group, what the honest limitations are, and what the data does not yet tell us

Abstract: The US adult obesity rate has declined from 39.9% in 2022 to 36.4% in 2026, representing approximately 7.6 million fewer obese adults. The decline is statistically significant and coincides with a dramatic increase in GLP-1 receptor agonist use for weight loss, from 3% of adults in 2024 to 11% in 2026 per Gallup, with 15% reporting lifetime use. GLP-1 medications (semaglutide brands Ozempic and Wegovy; tirzepatide brands Zepbound and Mounjaro) activate GLP-1 receptors in the brain, gut, and pancreas, slowing gastric emptying, suppressing appetite, and reducing food reward signaling in the brain. The biggest obesity reductions are in the 40-49 age group (down 4.3 points to 43.3%) and 50-64 group (down 5.0 points to 42.8%), which also have the highest GLP-1 usage rates (16.2% and 17.0% respectively). Adults 65+ show no reduction despite 11.1% usage, consistent with prior Gallup research showing reduced drug effectiveness in older adults. 68% of current users take brand-name medications; 19% use compounded (non-FDA-approved) versions. About 4 in 10 compounded users rated their medication extremely effective vs 32% of brand-name users. Diabetes rates have not declined and have reached a record high of 13.8% in 2026. The obesity data relies on self-reported height and weight, a method known to slightly underestimate true obesity prevalence. Whether the decline is sustained depends on continued drug access, pricing, and whether lifestyle changes accompany drug use.

Every Day Is a New Jersey. Every Entry Builds Toward Messi.

Each day through July 7, Kalshi gives away one signed, authenticated jersey from a World Cup icon. Miss a day, miss that jersey. But every day you check in earns you another entry toward the grand prize: the Messi jersey, game-worn from the match he scored his 800th career goal. Di María, Ochoa, Dempsey, Modrić, Falcao, Varane, Ferdinand, and Villa are all in the lineup. Download the Kalshi app and enter today's giveaway free. Share with a friend to earn a bonus entry toward Messi.

Check In Daily.

_{Free to enter. App required. No purchase necessary. 18+, U.S. only (excl. NY & FL).}

1. The Numbers: What Has Actually Changed 📊📉

Obesity has climbed in the US since Gallup began ongoing measurement in 2008, increasing over 14 percentage points to 39.9% by 2022 amid wide-ranging declines in physical health over the course of the COVID-19 pandemic.

The drop since then is the first sustained decline in that entire measurement period.

The rate among men has dropped 2.3 percentage points to 35.2% in 2025, while women's rate has dropped 3.5 points to 38.8%.

The biggest reduction is among those aged 40-49, whose obesity rate has fallen 4.3 points to 43.3%, and those aged 50-64, down 5.0 points to 42.8%.

Crucially, those are exactly the age groups with the highest GLP-1 usage rates.

Adults under 30 and over 65 show almost no change. And the over-65 group, despite reasonably high drug usage at 11.1%, shows no obesity reduction at all, consistent with earlier research showing GLP-1 medications are simply less effective in older adults.

The pattern is not random. It maps almost perfectly onto who is taking the drugs.

2. How GLP-1 Drugs Actually Work 💉🧠

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating.

It does three things: signals to the pancreas to release insulin, slows down how fast food leaves the stomach, and tells the brain that you are full.

The drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) mimic and amplify this hormone.

GLP-1 is a natural hormone in the body that slows digestion, controls appetite, and regulates blood sugar.

Medications such as semaglutide activate the same pathways in the brain, providing a new means of helping manage weight.

What makes these drugs different from previous weight loss medications is the brain component. They reduce the reward signal food produces in the brain, not just the hunger signal.

People on semaglutide often report that food simply becomes less interesting. The craving mechanism is quieted at a neurological level, not just suppressed through willpower.

Brand-name medications such as Ozempic or Wegovy comprise 68% of current usage. Another 19% of users take compounded or custom-mixed versions, which are designed to copy the effects of a brand-name drug but are not FDA-approved.

3. The Honest Limitations of the Data ⚠️🔍

The good news is real. The caveats are also real.

The data is self-reported. Gallup polls rely on self-reporting and are not peer reviewed, making the data less robust than measures taken directly by researchers.

Self-reported height and weight are known to slightly underestimate true obesity prevalence. The real baseline was probably higher than 39.9%, which means the real current rate may be higher than 36.4%.

Correlation is not causation. While there is no direct proof that GLP-1 drugs are driving the drops in obesity rates, given their increasing use and how effective they are known to be, it seems likely.

But diet trends, economic factors, and post-COVID behavioral changes are also present in the same period.

Diabetes is not improving. Diagnoses of type 1 or type 2 diabetes among US adults are now up to a record high of 13.8%. Obesity and diabetes are deeply linked, but diabetes is a lifelong condition and would not reverse quickly even if obesity declined. This will be the real test of whether the obesity drop has lasting metabolic consequences.

Sustainability is unknown. Whether these advances translate into lasting improvement will depend on continued access, surveillance, and broader changes in public health behaviors. GLP-1 drugs are expensive, access is unequal, and the weight returns when people stop taking them.

4. What This Actually Means 🔭🌍

The obesity drop is significant regardless of its source.

This equates to around 7.6 million fewer people being counted as obese, meaning a potential future reduction in obesity-related health conditions, including cancer, heart disease, stroke, and mental health issues.

Reducing the obesity rate is a goal that has been in place since 2001, when former Surgeon General David Satcher issued a landmark call to action, citing obesity's contribution to nearly 300,000 American deaths annually.

For 25 years, that goal moved in the wrong direction.

Weight loss from GLP-1s is not just cosmetic. A steady drumbeat of research has found that the drugs lower the health risk from obesity-related conditions. Increasing access could prevent a lot of illness and premature death.

The bigger question is not whether these drugs work. It is whether the people who need them most will ever be able to afford them. Currently, 13 states fully cover GLP-1s for obesity treatment under Medicaid, and legislative efforts continue to target expanded coverage.

If the decline in obesity accelerates as access widens, this will be remembered as one of the most consequential pharmaceutical developments in public health history.

If access remains limited, the 7.6 million figure will not grow much further.

Takeaways

• The US adult obesity rate has dropped from 39.9% in 2022 to 36.4% in 2026, the first sustained decline since Gallup began measurement in 2008, representing approximately 7.6 million fewer adults classified as obese; the biggest reductions are in the 40-49 and 50-64 age groups (down 4.3 and 5.0 points respectively), which are also the groups with the highest GLP-1 drug usage rates, while adults over 65 show no reduction despite drug use, consistent with prior research showing reduced effectiveness in older adults.

• GLP-1 medications (semaglutide as Ozempic and Wegovy, tirzepatide as Zepbound and Mounjaro) work by mimicking the gut hormone that slows digestion, suppresses appetite, and reduces food reward signaling in the brain; adult usage has risen from 3% in 2024 to 11% in 2026 with 15% reporting lifetime use, with 68% using brand-name versions and 19% using compounded non-FDA-approved alternatives, while diabetes rates have simultaneously reached a record high of 13.8%, reflecting the long lag between obesity reduction and metabolic disease reversal.

• The data has real limitations: it relies on self-reported measurements, direct causal proof linking GLP-1 use to the obesity drop does not yet exist, the weight returns when people stop taking the drugs, and only 13 states cover GLP-1s under Medicaid, meaning the sustainability of the decline depends almost entirely on whether drug access expands to the populations that need it most.

Wake Up Smarter About AI.

The president of OpenAI. The CEO of Google. The founder of LinkedIn. We talk to the people building AI. Every morning, we put what they told us in your inbox.

What they're actually worried about. What they're betting on. What's coming next. Delivered in five minutes, before your first meeting.

With one email, and only five minutes, you can stay ahead of 99% of the world.

Join 75K Readers →